Faldaprevir sodium  (Synonyms: BI 201335 sodium)

Faldaprevir sodium is a potent, orally active and selective noncovalent inhibitor of NS3/4A protease of HCV (hepatitis C virus) genotypes 1a and 1b, with K_i values of 2.6 and 2.0 nM, respectively. Faldaprevir sodium inhibits HCV RNA replication, with EC₅₀ values of 6.5 and 3.1 nM, respectively. Faldaprevir sodium has potent antiviral activity against chronic HCV infection^[1][2].

891.80

C₄₀H₄₈BrN₆NaO₉S

1215856-44-2

O=C([C@H]1N(C[C@@H](C1)OC2=CC(C3=CSC(NC(C(C)C)=O)=N3)=NC4=C2C=CC(OC)=C4Br)C([C@H](C(C)(C)C)NC(OC5CCCC5)=O)=O)N[C@]6([C@@H](C6)C=C)C(O[Na])=O

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Llinàs-Brunet M, et al. Discovery of a potent and selective noncovalent linear inhibitor of the hepatitis C virus NS3 protease (BI 201335). J Med Chem. 2010 Sep 9;53(17):6466-76.  [Content Brief]

  [2]. Zeuzem S, et al. Faldaprevir (BI 201335), deleobuvir (BI 207127) and ribavirin oral therapy for treatment-naive HCV genotype 1: SOUND-C1 final results. Antivir Ther. 2013;18(8):1015-9.  [Content Brief]